Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 31

Results For "ANDA"

2089 News Found

Zydus receives final approval from USFDA for Ibuprofen and Famotidine Tablets, 800 mg/26.6 mg
Drug Approval | February 22, 2025

Zydus receives final approval from USFDA for Ibuprofen and Famotidine Tablets, 800 mg/26.6 mg

Ibuprofen and famotidine combination is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis


India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
interviews | February 21, 2025

India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant

We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner


Korea’s MFDS completes inspection at Concord Biotech's Dholka unit
Drug Approval | February 21, 2025

Korea’s MFDS completes inspection at Concord Biotech's Dholka unit

The inspection was successfully completed


Lupin receives EIR from USFDA for its Somerset manufacturing facility
Drug Approval | February 21, 2025

Lupin receives EIR from USFDA for its Somerset manufacturing facility

the inspection conducted from January 27 to January 31, 2025


Orchid Pharma's Alathur API facility successfully completes USFDA inspection
Drug Approval | February 20, 2025

Orchid Pharma's Alathur API facility successfully completes USFDA inspection

The Alathur facility specializes in the production of Cephalosporin antibiotics


Boehringer's zongertinib receives Priority Review from USFDA for the treatment of HER2 mutant advanced non-small cell lung cancer
Drug Approval | February 20, 2025

Boehringer's zongertinib receives Priority Review from USFDA for the treatment of HER2 mutant advanced non-small cell lung cancer

Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved


Lupin receives “A-” leadership rating from CDP in climate change and water security
Sustainability | February 19, 2025

Lupin receives “A-” leadership rating from CDP in climate change and water security

This rating reflects Lupin's leadership in environmental transparency and performance


EyeQ upgrades eye care facility in Surat
Healthcare | February 18, 2025

EyeQ upgrades eye care facility in Surat

Theatre (OTs) dedicated to cataract, LASIK, and retina treatments added to meet the growing demand


Imfinzi perioperative regimen improved survival across muscle-invasive bladder cancer patients
News | February 15, 2025

Imfinzi perioperative regimen improved survival across muscle-invasive bladder cancer patients

Imfinzi reduced the risk of distant metastases and death from bladder cancer vs. neoadjuvant chemotherapy alone


Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial
News | February 15, 2025

Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial

The safety profile of Opdualag observed in this analysis was consistent with the known profiles of nivolumab and relatlimab